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Erk1/2Acetylcholine (ACh), a classical neurotransmitter, has been shown to be present in various non-neuronal cells,
including cells of the eye, such as corneal epithelium and endothelium, and to havewidespread physiological ef-
fects such as cytoskeleton reorganization, cellular proliferation, differentiation, and apoptosis. The aim of this
study was to investigate the effect of ACh on corneal keratocyte proliferation, and the underlying mechanisms,
in order to explore its possible effect in corneal wound healing. Primary culture of human keratocytes was
established from donated corneas. Cell viability and fraction of proliferating cells were detected by MTS assay
and BrdU incorporation ELISA, respectively. Expression of proliferative markers, PCNA and Ki-67, was detected
by western blot and immunocytochemistry. Activation of the MAPK/Erk signaling pathway and its involvement
in ACh-enhanced proliferation was determined by western blot analysis, MTS, and BrdU ELISA. We found that
ACh enhanced keratocyte proliferation even at low concentrations. Stimulation of proliferation was mediated
through activation of muscarinic ACh receptors (mAChRs). Western blot analysis revealed that ACh stimulation
of keratocytes upregulated the expression of PCNA and Ki-67, and Ki-67 immunocytochemistry showed that
ACh-treated cellswere in an active phase of the cell cycle. ACh activatedMAPK signaling, and this stepwas crucial
for the ACh-enhanced proliferation, as inhibition of the MAPK pathway resulted in ACh having no proliferative
effect. In conclusion, ACh enhances keratocyte proliferation and might thus play a role in proper corneal
wound healing.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Acetylcholine (ACh) is regarded as a classical neurotransmitter well
known for acting in the central and peripheral nervous system, and to
be present in both prokaryotes and eukaryotes [1–3]. However, in re-
cent years, there have been extensive evidence demonstrating a non-
neuronal cholinergic system, in which ACh and/or its synthesizing en-
zyme, choline acetyltranferase (ChAT), have been found to be present
in non-neuronal human cells, such as keratinocytes [1,4], epithelial [5]
and endothelial [6] cells, tendons [7], and various cells of the immune
system [3]. ACh has been shown to have widespread physiological ef-
fects such as cytoskeleton reorganization, cellular proliferation, differ-
entiation, and apoptosis [1,3,8,9]. Most cell types not innervated by
cholinergic neurons still express two types of ACh receptors [10]: nico-
tinic (nAChRs), which are ion channels, or G protein-coupledmuscarin-
ic receptors (mAChRs). Activation of these receptors has been linked to
activation of mitogen-activated protein kinase (MAPK)-dependent
pathways [9,11,12], in which phosphorylation of Erk1/2 leads to DNA
synthesis and cell proliferation [13].a).
. This is an open access article underThe cornea is the transparent front part of the eye and is composed
of three distinct layers: an outermost epithelial layer, a middle, trans-
parent stromal layer, and an innermost endothelial layer. The stromaac-
counts for up to 90% of the corneal thickness and it is made of collagen
ﬁbrils in between which the quiescent cells of the stroma, the
keratocytes, reside. The main role of these cells is maintenance and re-
pair of the stroma [14–16]. ACh and ACh receptors have been studied
in the cornea; however,most of the studies have been conducted in cor-
neal epithelium and endothelium. Corneal epithelium has been shown
to contain high concentrations of ACh and its synthesizing enzymes
ChAT, and both corneal epithelium and endothelium express mAChRs
[17]. There has been less attention to expression of nAChRs in the cor-
nea. However, a recent study has shown that corneal epithelium ex-
presses several nAChRs, including both α7 and α9 homomeric nAChRs
and predominantly the α3β2 ± α5 subtype of heteromeric nAChRs
[18]. The role of ACh in the cornea remains unclear, but data suggest
that ACh plays an important role in epithelial regrowth after corneal in-
jury and that it promotes chemotaxis [18], therefore facilitating healing
of the injured cornea. Recent ﬁndings in our lab have shown that in vitro
cultured human keratocytes secrete ACh and express mAChRs of sub-
types M1, M3, M4, andM5 (unpublished data). Nevertheless, the knowl-
edge on theACh system in the corneal stroma, and its keratocytes, is stillthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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al wound healing requires studies on the stromal components. There-
fore, in the present study, we evaluate the role ACh in keratocyte
proliferation and thus its possible role in corneal wound healing.
2. Materials and methods
2.1. Collection of human corneas
Healthy human corneas from deceased individuals who had chosen,
when alive, to donate their corneas post-mortem for transplantation or
research, according to Swedish law, were kept in a corneal biobank at
the University Hospital of Umeå, Sweden. If these healthy donated cor-
neas were not used for transplantation after their collection, they were
delivered to the laboratory for research purpose. If corneas were used
for transplantation, some or all of the transplantation graft leftovers
were retrieved for study purpose: the healthy donor peripheral part or
the healthy donor anterior or posterior central lamella. The study was
vetted by the Regional Ethical Review Board in Umeå (2010-373-
31 M) without objections. The study was performed according to the
principles of the Declaration of Helsinki.
2.2. Chemicals and reagents
Acetylcholine, mecamylamine, atropine, and collagenase were pur-
chased from Sigma–Aldrich (Saint Louis, MO, USA). PD98059 was ob-
tained from Calbiochem (San Diego, CA, USA). Antibodies against β-
actin, p-Erk1/2 (Thr202/Tyr204), and PCNA were purchased from Cell
Signaling (Danvers, MA, USA). Ki-67 antibody was obtained from
Millipore (Billerica, MA, USA). Cell viability assay was purchased from
Promega (Fitchburg,WI, USA). BrdU incorporation ELISAwas purchased
from Roche (Basel, Switzerland). DMEM/F-12 + GlutaMAX™medium,
penicillin-streptomycin, FBS, and Trypsin-EDTA were obtained from
Life Technologies (Carlsbad, CA, USA).
2.3. Isolation and primary culture of human corneal stromal cells
Primary culture of human keratocyteswas established byﬁrst scrap-
ing off any remaining epithelial and endothelial cells from a donated
cornea, and then separating and mincing central and peripheral parts
with a scalpel. Samples were then digested in 2 mg/ml collagenase di-
luted in DMEM/F-12 + GlutaMAX™ medium overnight at 37 °C. The
samples were then transferred to DMEM / F-12 GlutaMAX™ medium
supplementedwith 2% FBS and 1% penicillin-streptomycin and cultured
at 37 °C with 5% CO2. Medium was replaced every second to third day
until the cells reached conﬂuence. Conﬂuent cells were detached with
0.05% Trypsin-EDTA and split in a 1:2 ratio. Cells from the central cornea
in passages 4 to 5 were used for experiments. DMEM/F-12 GlutaMAX™
medium supplemented with 0.1% FBS was used both for seeding cells
and performing experiments. In total, 12 corneas were used for experi-
ments. The corneas were assessed individually.
2.4. Cell viability assay
The effect of ACh on the viability and proliferation of cells was mea-
sured using MTS assay (CellTiter 96® Aqueous One Solution Cell
Proliferation Assay) according to manufacturer's instructions. Brieﬂy,
keratocytes at a density of 2 × 103/well were seeded in a 96-well plate
overnight and treated with various concentrations of ACh for 24 h. To
assess type of ACh receptors responsible for ACh effect on proliferation,
cells were pretreated with various concentrations of atropine (musca-
rinic receptors antagonist) and mecamylamine (nicotinic receptors an-
tagonist). Moreover, to assess involvement of MAP kinase cascade in
ACh-induced proliferation, cells were pretreated with 25 μM PD98059
(MAP kinase inhibitor). Next, 20 μl of the MTS reagent was added into
each well and cells were incubated for 4 h at 37 °C, 5% CO2. To measurethe amount of formazan produced by cellular reduction of MTS, absor-
bance at 490 nmwas measured with a micro-plate reader (BioTek, Wi-
nooski, VT, USA).2.5. BrdU incorporation ELISA
ACh effect on cell proliferation was performed by measurement of
BrdU incorporation in newly synthesized cellular DNA according to
manufacturer's instructions. Brieﬂy, 3 × 103 keratocytes were seeded
into 96-well plate overnight and treated with various concentrations
of ACh. Additionally, cells were pretreated with atropine, mecamyl-
amine, or PD98059 as described in a previous section. One hour after
treatments, cells were labeled with 10 μM BrdU and incubated for
24 h at 37 °C, 5% CO2. Next, cells were ﬁxed and theDNAwas denatured.
Anti-BrdU-POD was added to bind BrdU incorporated in newly synthe-
sized DNA. Immune complexes were detected by measuring the absor-
bance at 370 nm(with a referencewavelength at 492 nm)with amicro-
plate reader (BioTek).2.6. Western blot analysis
2.5 × 105 cells/well were plated in 6-well plates. In order to block
muscarinic or nicotinic receptors, cells were treated with atropine or
mecamylamine for 30 minutes. Afterwards, cells were treated with A-
Ch. After indicated time, keratocytes were washed with PBS and
freeze/thawed 3 times. Cells were further lysed in RIPA buffer supple-
mented with proteinase and phosphatase inhibitor cocktail (Fisher Sci-
entiﬁc, Waltham, MA, USA). Protein concentration was assessed by
Bradford assay (Bio-Rad, Hercules, CA, USA). Aliquots of the lysates
(12 μg for p-Erk1/2 (Thr202/Tyr204); 30 μg for PCNA and Ki67 studies)
were separated on either 4–20% or 7.5% (Ki67) SDS–polyacrylamide gel
and transferred to PVDFmembranes. After blockingwith either 5% non-
fat dry milk or 5% BSA, membranes were incubated with primary anti-
bodies at 4 °C overnight. Then, the membranes were incubated with
HRP-conjugated antibodies for 1 h at room temperature. Images were
taken by Odyssey® Fc imaging system (LI-COR, Lincoln, NE, USA). Den-
sitometry was performed using Image J analysis software (NIH).2.7. Immunocytochemistry
104 cells per well were seeded in an 8-well chamber slides (Corning,
Corning, NY) overnight. Cells were treatedwith 10−7M ACh. After 24 h,
medium was removed and cells were washed twice with PBS.
Keratocytes were ﬁxed with 3.7% paraformaldehyde in 1 × PBS for
5 minutes at room temperature, and then blocked for 15 minutes with
rabbit normal serum in PBS (1:20). Cells were incubated with Ki-67 an-
tibody (1:200) for 1 h at 37 °C and blocked again for 15 minutes with
rabbit normal serum in PBS (1:10). After washing, secondary antibody
labeled with TRITC (Dako, Glostrup, Denmark) was incubated with the
cells for 30 minutes at 37 °C. Finally, cells were mounted in ProLong®
Diamond Antifade Mountant with DAPI (Life Technologies). A control
well was also prepared for secondary antibody by replacing the primary
antibody with PBS. A Zeiss Axioskop 2 plus microscope equipped with
epiﬂuorescence and an Olympus DP70 digital camera were used for
analysis.2.8. Statistical analysis
All experiments were performed in triplicates. Data are presented as
mean ± SD. Statistical analysis was carried out using one-way or two-
way ANOVA and Bonferroni post hoc test. Differences were considered
statistically signiﬁcant at a p value of b 0.05. The experiments were re-
peated successfully at least three times.
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3.1. Acetylcholine enhances keratocyte proliferation
The potential effect of ACh on keratocyte proliferationwas evaluated
byMTS assay (Fig. 1A) and BrdUELISA (Fig. 1B). The results showed that
the lower concentrations of ACh used (10−8 and 10−7) enhanced cell
proliferation. The higher concentration of ACh (10−6 M), however, did
not show a signiﬁcant effect on proliferation in either method.
Since migration of keratocytes is another important step of corneal
wound healing, the involvement of ACh in this step was also studied.
ACh had no stimulatory effect on keratocyte migration as assessed by
migration assay (data not shown).3.2. Acetylcholine enhances keratocyte proliferation through activation of
muscarinic acetylcholine receptors
In order to study throughwhich type of receptors ACh exerts its pro-
liferative effect, keratocytes were treated with different concentrations
of mecamylemine (nAChR antagonist) or atropine (mAChR antagonist)
for 30 minutes. Afterwards, cells were treated with various concentra-
tions of ACh (10−8, 10−7, and 10−6 M) for 24 h. Cell proliferation was
assessed by MTS assay and BrdU ELISA. The results showed that treat-
ment of cells with mecamylamine did not abolish the ACh proliferative
effect on keratocytes (Fig. 2A). However, treatment of cells with atro-
pine resulted in the proliferative effect of ACh being reduced (Fig. 2B),
suggesting mAChR involvement in ACh signaling.Fig. 1. Acetylcholine enhances keratocyte proliferation. Human keratocytes were cultured
with different concentrations of acetylcholine (ACh) for 24 h. ACh was found to promote
proliferation at the lower concentrations as assessed byMTS assay (A) and BrdU incorpo-
ration (B). Values are means ± SD. n.s. (not signiﬁcant), p N 0.05; *p b 0.05; **p b 0.01.Moreover, to test whether removal of keratocytes from collagenma-
trix in the cornea has an effect on mAChR and nAChR expression in cul-
tured keratocytes, cells were grown on either collagen I coated 6-well
plates or standard polystyrene 6-well plates. Expression was assessed
by RT-qPCR and western blot. No differences in mAChR and nAChR
mRNA levels were found. However, western blot analysis revealed
that mAChR subtype M1, mAChR subtype M3, and mAChR subtype M5
were expressed in higher amounts by keratocytes grown on collagen I
layer than by keratocytes on standard plates (data not shown). Treat-
ment of keratocytes with 10−6 M ACh resulted in downregulation of
mAChR subtypeM3 on protein level, but the expression of the other re-
ceptor subtypes was not affected (data not shown). The latter experi-
ment was performed to determine whether a change in receptor
expression might explain the absent proliferative effect of the higher
ACh concentration.
3.3. Acetylcholine stimulation upregulates expression of PCNA and Ki-67
proliferation markers
PCNA and Ki-67 are well-known and approved cell proliferation
markers [19,20]. In order to establish if ACh stimulation leads to in-
creased expression of these markers, western blot (Fig. 3A and B) and
immunocytochemistry (Fig. 3C) were performed.Western blot analysis
showed that cells treated with 10−6 M ACh have upregulated PCNA ex-
pression. However, such effect could not be observed with 10−8 M
ACh. Ki-67 expression was upregulated for both 10−6 and 10−8 M
ACh treatment. Blocking mAChRs with 10−5 M atropine resulted in
downregulation of both PCNA and Ki-67 proteins in cells treated with
10−6 M ACh, however, not in the cells treatedwith 10−8 M ACh. nAChR
blockage did not affect PCNA or Ki-67 upregulation by ACh. To further
analyze expression of Ki-67, ACh (10−7 M)-treated keratocytes were
immunostained with Ki-67 antibody (Fig. 3C). Untreated cells showed
no Ki-67 expression, on the other hand, cells treated with ACh showed
Ki-67 expression, which was localized to the nuclei.
3.4. Acetylcholine stimulation leads to Erk1/2 phosphorylation
ACh signaling has been shown to activate MAP kinases (Erk1/2) in
different cell types [9,11,12]. Therefore, we checked whether stimula-
tion of keratocytes with ACh leads to phosphorylation (i.e. activation)
of these speciﬁc kinases. Western blot analysis showed that ACh stimu-
lation of keratocytes leads to enhanced Erk1/2 phosphorylation, as
compared to control, with a peak at 30 minutes after stimulation.
Pretreatment with 10−5 M of atropine to block mAChRs resulted in re-
duced Erk1/2 phosphorylation after ACh stimulation as compared to
ACh stimulation without a blocker. Blocking nAChRs with 100 nMmec-
amylamine also led to reduced phosphorylation of Erk1/2 after ACh
stimulation as compared to ACh stimulationwithout a blocker, although
the phosphorylation after nAChR blockage was more prominent than
for atropine-treated cells. (Fig. 4A). Furthermore, to study if activation
of Erk1/2 is essential for ACh-enhanced proliferation, cells were treated
with 25 μMPD98059, an Erk1/2 inhibitor, and ACh of various concentra-
tions (10−8, 10−7, 10−8 M). Inhibiting Erk1/2 resulted in no enhance-
ment of cell proliferation by ACh (Fig. 4B), which suggests that
activation of Erk1/2 is essential for ACh signaling leading to proliferation
in keratocytes.
4. Discussion
This study shows that human keratocytes, when exposed to ACh, are
stimulated to proliferate via mAChRs and to activate the MAPK/Erk
pathway. Previous reports have shown positive effects of ACh on prolif-
eration of murine embryonal carcinoma cells [9], human lung ﬁbro-
blasts [21], and human tenocytes [22]. In human keratocytes, we
observed that after 24 h, both the number of viable cells and number
of cells in the S-phase of the cell cycle (BrdU incorporation) were
Fig. 2. Acetylcholine enhances keratocyte proliferation through activation of muscarinic acetylcholine receptors. Human keratocytes were pretreated with different concentrations of the
nicotinic acetylcholine receptor antagonist mecamylamine (Mec; A) or the muscarinic acetylcholine receptor antagonist atropine (B) for 30 minutes and afterwards treated with various
concentrations of acetylcholine (ACh) for 24 h. Cell proliferation was assessed byMTS and BrdU incorporation. Atropine was found to reduce ACh-stimulated proliferation, whereas mec-
amylamine did not have that effect, suggesting that theproliferative effect of ACh ismediated bymuscarinic ACh receptors. Values aremeans±SD. n.s. (not signiﬁcant), p N 0.05; *p b 0.05;
**p b 0.01.
Fig. 3. Acetylcholine stimulation upregulates expression of proliferation markers PCNA and Ki-67. (A) Human keratocytes were pretreated with either atropine or mecamylamine (Mec)
for 30minutes and afterwards treated with two concentrations of acetylcholine (ACh; 10−6 and 10−8 M) for 24 h. Expression of PCNA (36 kDa) and Ki-67 (345 and 395 kDa) was deter-
mined by western blot. β-actin (42 kDa) served as a loading control. ACh increased expression of both Ki-67 and PCNA. This increase was blocked with atropine but not mecamylamine,
thus indicating that theACh effectwas exerted throughmuscarinic ACh receptors. (B) Densitometric analysis of PCNAandKi-67 expression on thewesternblot. (C) Immunocytochemistry
of human keratocytes in culture shows that when treated with 10−7 M of ACh for 24 h, the cells display clear Ki-67 (red) reactions, which are not seen without the ACh treatment (left
column). Representative pictures are shown. DAPI (blue) counter-staining of nuclei shown in themiddle column;merge to the right. Values aremeans±SD. n.s. (not signiﬁcant), p N 0.05;
**p b 0.01; ***p b 0.001.
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Fig. 4.Acetylcholine stimulation leads to Erk1/2 phosphorylation. (A) Human keratocytes were pretreatedwith 10−5 M atropine or 100 nMmecamylamine (Mec). Afterwards, cells were
treatedwith 10−7M of acetylcholine (ACh) for 10, 20, 30, and 45minutes. Phosphorylation status of Erk1/2 (42 and 44 kDa)was determined bywestern blot. β-actin (42 kDa) served as a
loading control. ACh increased phosphorylation of Erk1/2with a peak at 30min. Cells treatedwith atropine ormecamylamine andACh showeddecreased Erk1/2 phosphorylation as com-
pared to cells only treated with ACh. However, atropine treatment resulted in less Erk1/2 phosphorylation when compared to mecamylamine treatment. (B) Activation of Erk1/2 was
found to be essential for ACh-induced proliferation, as seen when keratocytes were pretreated with PD98059, an Erk1/2 inhibitor, for 1 h and afterwards treated with various concentra-
tions of ACh (10−8, 10−7, and 10−6 M) for 24 h. Cell proliferation was measured byMTS assay and BrdU incorporation, and the ACh stimulated proliferation was found to be signiﬁcantly
decreased when preincubated with the Erk1/2 blocker. Values are means ± SD. n.s. (not signiﬁcant), p N 0.05; **p b 0.01; ***p b 0.001.
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10−8M and 10−7M as comparedwith unstimulated cells. Interestingly,
higher concentration of ACh (10−6M) did not stimulate keratocyte pro-
liferation. Proliferating cell nuclear antigen (PCNA), which is a well-
accepted marker of proliferation and is a member of the DNA sliding
clamp family of proteins that assist in DNA replication [19], was upreg-
ulated after ACh stimulation of keratocytes. Similarly, Ki-67 which is
also a marker of proliferation and is present during all active phases of
the cell cycle (G1, S, G2, and mitosis) but is absent from resting cells
(G0) [20], was upregulated in response to ACh. However, the higher
concentration of ACh (10−6 M) resulted in higher PCNA and Ki-67 ex-
pression than treatment with lower concentration of ACh (10−8 M).
The lower efﬁciency of high ACh concentration to increase the number
of viable cells and BrdU incorporation into newly synthesized DNA
might occur due to ACh receptor desensitization. It is known that high
concentrations of ACh cause downregulation of muscarinic receptors
which is generally accompanied by decreased sensitivity to muscarinic
agonists [23–25]. Indeed, we did observe that a high concentration of
ACh downregulates the expression of mAChR subtype M3, a subtype
of mAChR that has in fact been reported to mediate cell proliferation
[26]. Alternatively, these effects might be due to activation of a different
mechanism by ACh stimulation, since low ACh concentrations have
been shown to cause a calcium-independent stimulation of prolifera-
tion of rat lymphoblasts, whereas higher ACh concentrations act
through calcium-dependent mechanisms [27]. However, our experi-
ments showed that high concentration of ACh resulted in higher PCNA
and Ki-67 protein expression than low concentration treatment. As
the endpoint of proliferation is an increase in cell number, and both
PCNA and Ki-67 are taking part in committing the cell into proliferation,
perhaps a high concentration of ACh results in post-translational modi-
ﬁcations of these two proteins which would stop the cell from dividing
[28,29]. Additionally, the removal of keratocytes from the cornea and
their processing during culturing causes downregulation of mAChRs,
whichmight explainwhywe donot observe amore robust proliferation
of cultured keratocytes after ACh stimulation.
The role of mAChRs in control of the cell proliferation is well known.
For example, activation of mAChR subtype M2 and mAChR subtype M3
has been shown to increase proliferation of tumor cells [30] andﬁbroblasts [21]. However, the involvement of nAChR in control of cell
proliferation is less well understood. Nevertheless, there are data sug-
gesting that activation of these receptors might lead to migration, sur-
vival, and differentiation in oligodendrocyte precursors [31] as well as
proliferation in human non-small cell lung cancer cells [32]. Our results
indicate that ACh-enhanced proliferation of keratocytes is driven
through activation of mAChRs rather than nAChRs. We observed that
mecamylamine, a nonselective and noncompetitive antagonist of
nAChRs, did not abolish the proliferative effects of ACh, as the number
of viable cells, the numbers of cells with incorporated BrdU, and the ex-
pression of PCNA andKi-67 remained either unchanged (when low con-
centrations of ACh were used) or showed slightly higher cell numbers
and protein expression (at higher concentrations of ACh). However,
when atropine, a competitive mAChR antagonist, was used, ACh treat-
ment did not stimulate keratocytes to proliferate; neither viable cell
count nor BrdU incorporation increased, and expression of both PCNA
and Ki-67 was downregulated. It is known that ACh-induced prolifera-
tion is mediated by activation of MAPK-dependent pathways [11,33]
and that activation of MAPK agonists mediate cell proliferation [34,
35]. Furthermore, pathways involving cholinergic receptors seem to
be dependent on the cell growth [9,36]. MEK1 and MEK2, also called
MAPK or Erk kinases, are dual-speciﬁcity protein kinases that function
in a mitogen-activated protein kinase cascade controlling cell growth
anddifferentiation [37]. Our results showed that in keratocytes, ACh sig-
nals through activation of MAPK (Erk1/2) and that this activation is me-
diated mostly via mAChRs and to lesser extent via nAChRs. Moreover,
activation of this pathway was found to be essential for ACh-stimulated
proliferation, as the proliferative effect of ACh on keratocytes was
abolished when PD98059, a highly selective inhibitor of MEK1 activa-
tion and the MAP kinase cascade, was used.
The cornea which is normally well protected from injury might
under some circumstances, such as infection or trauma, become injured.
When this happens, a healing cascade is activated. Brieﬂy, this complex
process starts with apoptosis of the keratocytes adjacent to the injury
site. Subsequently, the remaining keratocytes start to proliferate and
migrate in order to ﬁll the wound. Eventually, new extracellular matrix
is produced and the functionality of the cornea is restored [38,39]. How-
ever, the wound-healing process can malfunction and, as a result,
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ment or even blindness [40]. It is therefore of great value to study sub-
stances that are involved in, or may contribute to, effective corneal
wound healing. In this regard, ACh is of interest since it has been impli-
cated in corneal epithelial and endothelial wound healing [17,18]. How-
ever, themechanisms of ACh activity remain unclear and the role of ACh
in the stroma is also unknown. Therefore, our ﬁndings that ACh en-
hances proliferation of corneal stromal keratocytes in vitro, through ac-
tivation of mAChRs and the MAPK/Erk signaling pathway, provide new
insights into understanding the mechanisms of ACh signaling in
keratocytes and its possible implication in promoting corneal stromal
wound healing.
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